Current status of multimodal therapy for colorectal liver metastases;Kolorektale Lebermetastasen: Aktueller Stand der multimodalen Therapie

Zentralblatt fur Chirurgie - Zeitschrift fur Allgemeine, Viszeral- und Gefasschirurgie

Volumn 136, Issue 4, 2011, Pages 343-351

  Seehofer, D ^a   Neuhaus, P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

liver metastasis; liver resection; multimodal treatment; neoadjuvant chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ALGORITHM; ARTICLE; ARTIFICIAL EMBOLISM; CATHETER ABLATION; CLINICAL TRIAL (TOPIC); COLORECTAL TUMOR; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER RESECTION; LIVER TUMOR; METASTASIS; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REOPERATION; SURVIVAL RATE; VASCULARIZATION;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; HEPATECTOMY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; NEOADJUVANT THERAPY; REOPERATION; SURVIVAL RATE;

EID: 80052175965     PISSN: 0044409X     EISSN: 14389592     Source Type: Journal    
DOI: 10.1055/s-0031-1271579     Document Type: Article

References (68)

1. Kopetz S, Chang G J., Overman M J. et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009 27 3677-3683
2. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990 77 1241-1246
3. Neumann U P., Seehofer D, Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma. Dtsch Arztebl Int 2010 107 335-342
4. Stübs P, Habermann P, Wex C et al. Palliative Chemotherapie beim kolorektalen Karzinom Stand, Wertigkeit, Tendenzen. Zentralbl Chir 2010 135 535-540
5. Folprecht G, Gruenberger T, Bechstein W O. et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase2 trial. Lancet Oncol 2010 11 38-47
6. Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005 8 1311-1319 (Pubitemid 41158476)
7. Falcone A, Ricci S, Brunetti I et al. PhaseIII trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007 25 1670-1676 (Pubitemid 46797946)
8. Masi G, Loupakis F, Pollina L et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009 249 420-425
9. Saltz L B., Clarke S, Daz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phaseIII study. J Clin Oncol 2008 26 2013-2019
10. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009 20 1842-1847
11. Van Cutsem E, Köhne C H., Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009 360 1408-1417
12. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009 27 663-671
13. Garufi C, Torsello A, Tumolo S et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010 103 1542-1547
14. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009 27 663-671
15. Ricke J, Hildebrandt B, Miersch A et al. Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events. J Vasc Interv Radiol 2004 15 825-833 (Pubitemid 39063222)
16. Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009 8 CD007823
17. Elias D, Goere D, Boige V et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007 14 3188-3194 (Pubitemid 47594272)
18. Kemeny N E., Melendez F D., Capanu M et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009 27 3465-3471
19. Boige V, Malka D, Elias D et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008 15 219-226
20. Vauthey J N., Pawlik T M., Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006 24 2065-2072 (Pubitemid 46622116)
21. Aloia T, Sebagh M, Plasse M et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006 24 4983-4990 (Pubitemid 46631400)
22. Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004 15 460-466 (Pubitemid 38444550)
23. Rubbia-Brandt L, Lauwers G Y., Wang H et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin- associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010 56 430-439
24. Hubert C, Sempoux C, Horsmans Y et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int 2007 27 938-943 (Pubitemid 47261947)
25. Wicherts D A., de Haas R J., Sebagh M et al. Regenerative Nodular Hyperplasia of the Liver Related to Chemotherapy: Impact on Outcome of Liver Surgery for Colorectal Metastases. Ann Surg Oncol 2010 [Epub ahead of print]
26. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup Trial 40983): a randomised controlled trial. Lancet 2008 371 1007-1016 (Pubitemid 351392040)
27. Peppercorn P D., Reznek R H., Wilson P et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998 77 2008-2011 (Pubitemid 28254648)
28. McCormack L, Petrowsky H, Jochum W et al. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: A matched case-control study. Ann Surg 2007 245 923-930 (Pubitemid 46809294)
29. Brouquet A, Benoist S, Julie C et al. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146patients with colorectal metastases. Surgery 2009 145 362-371
30. Vauthey J N., Pawlik T M., Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006 24 2065-2072 (Pubitemid 46622116)
31. Mahfud M, Breitenstein S, El-Badry A M. et al. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg 2010 34 92-100
32. Klinger M, Eipeldauer S, Hacker S et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009 35 515-520
33. Pessaux P, Panaro F, Casnedi S et al. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. Eur J Surg Oncol 2010 36 575-582
34. Aussilhou B, Dokmak S, Faivre S et al. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 2009 16 1553-1559
35. Kishi Y, Zorzi D, Contreras C M. et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010 17 2870-2876
36. Glazer E S., Beaty K, Abdalla E K. et al. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010 145 340-345
37. Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008 26 1830-1835
38. Karoui M, Penna C, Amin-Hashem M et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006 243 1-7 (Pubitemid 43054046)
39. Lock J F., Westphal T, Malinowski M et al. Impact of neoadjuvant chemotherapy in colorectal liver metastases on liver function before hepatectomy (abstr.). HPB 2010 12 352
40. Overman M J., Maru D M., Charnsangavej C et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 2010 28 2549-2555
41. Stockmann M, Lock J F., Malinowski M et al. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 2010 12 139-146
42. Wicherts D A., de Haas R J., Andreani P et al. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg 2010 97 240-250
43. Kokudo N, Tada K, Seki M et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 2001 34 267-272 (Pubitemid 32702339)
44. Elias D, De Baere T, Roche A et al. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999 86 784-788 (Pubitemid 29271944)
45. Goéré D, Farges O, Leporrier J et al. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg 2006 10 365-370 (Pubitemid 43303830)
46. Beal I K., Anthony S, Papadopoulou A et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol 2006 79 473-478 (Pubitemid 43933443)
47. Covey A M., Brown K T., Jarnagin W R. et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 2008 247 451-455
48. Wicherts D A., Miller R, de Haas R J. et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 2008 248 994-1000
49. Jaeck D, Oussoultzoglou E, Rosso E et al. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 2004 240 1037-1049
50. Petrowsky H, Gonen M, Jarnagin W et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: A bi-institutional analysis. Ann Surg 2002 235 863-871 (Pubitemid 34547306)
51. Hopt U T., Drognitz O, Neeff H. Zeitlicher Ablauf von Leber- und Darmresektion bei Patienten mit kolorektalem Karzinom und synchronen Lebermetastasen. Zentralbl Chir 2009 134 425-429
52. Mentha G, Majno P E., Andres A et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006 93 872-878 (Pubitemid 44035261)
53. Brouquet A, Mortenson M M., Vauthey J N. et al. Surgical strategies for synchronous colorectal liver metastases in 156consecutive patients: classic, combined or reverse strategy? J Am Coll Surg 2010 210 934-941
54. de Haas R J., Wicherts D A., Flores E et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 2008 248 626-636
55. Adam R, Pascal G, Castaing D et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004 240 1052-1061
56. Allen P J., Kemeny N, Jarnagin W et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003 7 109-115
57. Neumann U P., Thelen A, Röcken C et al. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. Surgery 2009 146 52-59
58. Nordlinger B, Van Cutsem E, Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009 20 985-992
59. Schmiegel W, Reinacher-Schick A, Arnold D et al. S3-Leitlinie Kolorektales Karzinom Aktualisierung 2008. Z Gastroenterol 2008 46 799-840
60. Benoist S, Brouquet A, Penna C et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006 24 3939-3935
61. Adam R, Bhangui P, Poston G et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 2010 252 774-787
62. Mitry E, Fields A L., Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008 26 4906-4911
63. Parks R, Gonen M, Kemeny N et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007 204 753-761 (Pubitemid 46661187)
64. Ychou M, Hohenberger W, Thezenas S et al. A randomized phaseIII study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009 20 1964-1970
65. Helmberger T. Interventionelle Verfahren bei Lebermetastasen. Chirurg 2010 81 542-550
66. Elias D, Baton O, Sideris L et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol 2005 90 36-42 (Pubitemid 40446473)
67. Ruers T, van Coevorden F, Pierie J et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Interim results of a randomised phase II study of the EORTCNCRI CCSG-ALM Intergroup 40004 (CLOCC). 2008 Orlando, FL ASCO Gastrointestinal Cancers Symposium, abstr 4012
68. Ricke J, Mohnike K, Pech M et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2010 78 479-485